The experience of using cascade plasmofiltration in combined treatment with systemic lupus erythematosus on the background of programmed hemodialysis

• Published in: Bulletin of the Russian Military Medical Academy Vol. 20; no. 2; pp. 115 - 119
• Main Authors: Manuilov, A S, Bardakov, S N, Apchel, A V, Belskih, A N, Zakharov, M V, Tishko, V V, Ivanov, A M
• Format: Journal Article
• Language: English
• Published: 15.12.2018
• ISSN: 1682-7392; 2687-1424
• DOI: 10.17816/brmma12278

The results of combined treatment of systemic lupus erythematosus with the use of extracorporeal hemocorrection on the background of replacement therapy for kidney function are presented. The dynamics of the activity of the disease, assessed on the scales recommended by the European League against rheumatism, is presented. The analysis of humoral immunity indices and markers of inflammation before and after the application of efferent therapy methods is carried out. Thus, after applying the first operation cascade plasma filtration using fractionator plasma «Cascadeflo EC40», was a decrease in disease activity with a very high to a high degree, also decreased the activity of systemic lupus erythematosus with high to low degrees of activity after application of the second operation of systemic lupus erythematosus using plasma fractionator «Cascadeflo EC20». The results of combined treatment testify to the high effectiveness of therapeutic apheresis in the complex treatment of systemic lupus erythematosus. Operations cascade plasma filtration as part of combination immunosuppressive therapy allows to correct the main factors of the pathogenesis of systemic lupus erythematosus (antinuclear factor, antibodies to double-deoxyribonucleic acid, antibodies to histones, total immunoglobulins of classes G, M, A, circulating immune complexes, inflammation markers) selectively removing them from the vascular bed. Thus, the inclusion cascade plasmafiltration operation in the combined treatment of systemic lupus erythematosus, allows to quickly remove the main factors of the pathogenesis, which leads to a rapid decrease in the disease activity and reduces the dosages of cytostatic and glucocorticoid therapy.